NicOx.... in attesa di.....

[PIZZODIGINO]

dai Garufi tira fuori il coniglio dal cilindro.

 

[PIZZODIGINO]

dai Garufi fallo per noi, sigla un bell accordo.

 

[PIZZODIGINO]

dai Garufi dacci finalmente una bella soddisfazione.

 

[gigifiori]

Nicox’s Partner Secures Additional Approvals of VYZULTA (latanoprostene bunod ophthalmic solution), 0.024% in Hong Kong and Argentina
16/01/2020 07:30 RSF
For best results when printing this announcement, please click on link below: Read the announcement


Press Release
Nicox’s Partner Secures Additional Approvals of VYZULTA (®)(latanoprostene bunod ophthalmic solution), 0.024% in Hong Kong and Argentina
January 16, 2020 – release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that its partner, Bausch + Lomb, has received approval for VYZULTA (®)(latanoprostene bunod ophthalmic solution), 0.024% in Hong Kong and Argentina. With these approvals, VYZULTA is now approved for commercialization in a total of five countries and territories. VYZULTA is indicated for the reduction of intraocular pressure (IOP) in
patients with open-angle glaucoma or ocular hypertension. Nicox receives increasing tiered net royalties of 6% to 12% on global sales of VYZULTA as well as up to $150 million in potential future milestones. Bausch + Lomb is a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC).

 

[viralic]

Nicox’s Partner Secures Additional Approvals of VYZULTA (latanoprostene bunod ophthalmic solution), 0.024% in Hong Kong and Argentina
16/01/2020 07:30 RSF
For best results when printing this announcement, please click on link below: Read the announcement


Press Release
Nicox’s Partner Secures Additional Approvals of VYZULTA (®)(latanoprostene bunod ophthalmic solution), 0.024% in Hong Kong and Argentina
January 16, 2020 – release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that its partner, Bausch + Lomb, has received approval for VYZULTA (®)(latanoprostene bunod ophthalmic solution), 0.024% in Hong Kong and Argentina. With these approvals, VYZULTA is now approved for commercialization in a total of five countries and territories. VYZULTA is indicated for the reduction of intraocular pressure (IOP) in
patients with open-angle glaucoma or ocular hypertension. Nicox receives increasing tiered net royalties of 6% to 12% on global sales of VYZULTA as well as up to $150 million in potential future milestones. Bausch + Lomb is a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC).

Mancano ancora altri 15 paesi nel mondo in cui BHC ha chiesto l'approvazione.

 

[PIZZODIGINO]

bene, altri 6% che entrano.
e ora Garufi tira fuori l accordo

 

[viralic]

bene, altri 6% che entrano.
e ora Garufi tira fuori l accordo

Rinco come sono quelli di BAUSCH , si dimenticheranno di informare i medici dei paesi in cui è stato approvato e neppure inizierao a venderlo....sono una manica di incapaci e inetti... PARLO di BCH.

 

[elfrancese]

buena sera

 

[elfrancese]

vyzulta @ 3.500 TRX

 

[elfrancese]

un'altra scoperta personale, i risultati sono appena stati pubblicati sul sito web di ema riguardo a vyzulta ...
speriamo ... preghiamo ...

https://www.clinicaltrialsregister.eu/ctr-search/search?query=latanoprostene